medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2016, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2016; 25 (2)

Basal serum levels of immunoglobulins G, A, M, and E in the group of patients with cystic fibrosis at Hospital Infantil Universitario de San José Bogotá DC, in 2014

Ortega-López MC, Escobar QA, Barrero MDC

Language: English
References: 23
Page: 38-45
PDF size: 186.06 Kb.


ABSTRACT

Background: Patients with cystic fibrosis have poor lung function and chronic infections which impair the quality of life and are the leading cause of death. Hypogammaglobulinemia is associated with less severe lung disease; hypergammaglobulinemia with major lung impairment, presumably due to a hyperimmune response. Objective: Determine G, A, M, and E immunoglobulins serum levels in patients diagnosed with cystic fibrosis at Hospital Infantil Universitario de San José de Bogotá in 2014. Material and Methods: Case series of patients diagnosed with cystic fibrosis. Fifty three patients were included. Forty one samples of serum IgG, IgA, IgM, and IgE immunoglobulins were taken from patients without acute infectious disease, and who had not received gamma-globulin therapy or immunosuppressive therapy. Body mass index, lung function, bronchiectasis, and Pseudomonas aeruginosa colonization were assessed. Results: 51.2% of participants were male. The median age was 17.7 years; 58.5% of the patients had a normal BMI; the median FEV1 was 67.9%. The frequency of bronchiectasis was 39%, 31.7% were colonized with Pseudomona aeruginosa. Most of the patients had normal immunoglobulin levels; low levels of IgG were present in less than 5% of the patients. Patients with high IgG had bronchiectasis in 85.7%. High IgA was mainly present in male between 10 and 20 years old, who also had the worst respiratory impairment. They also had a greater colonization for more than three months. Bronchiectasis was found in 85% of the cases and was colonized by Pseudomonas aeruginosa. Conclusion: Increase in immunoglobulins levels correlate with bronchiectasis and inversely with FEV1.


REFERENCES

  1. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998; 132 (4): 589-595.

  2. Noticias Universia Colombia. Según investigación uno de cada 5.000 colombianos nace con fibrosis quística. Colombia, 3 agosto, 2010. [Accessed 28 September, 2015] URL disponible en: http://noticias.universia.net.co/vida-universitaria/noticia/2010/08/03/452555/investigacion-cada-5-000-colombianos-nace-fibrosis-quistica.html

  3. Vela D DCH, Flores C, Zavaleta A. Clinical Epidemiology Study of Cystic Fibrosis in the National Institute of Child Health, 2002-2011 Lima. Rev Peru Pediatr. 2014; 67: 9-16.

  4. Wallwork JC, Brenchley P, McCarthy J, Allan JD, Moss D, Ward AM et al. Some aspects of immunity in patients with cystic fibrosis. Clin Exp Immunoly. 1974; 18 (3): 303-320.

  5. Moss RB. Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Chest. 1987; 91 (4): 522-526.

  6. Garside JP, Kerrin DP, Brownlee KG, Gooi HC, Taylor JM, Conway SP. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr Pulmonol. 2005; 39 (2): 135-40.

  7. Lockitch G, Halstead AC, Quigley G, MacCallum C. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem. 1988; 34 (8): 1618-1621.

  8. Orozco L, Chávez M, Saldaña Y, Velázquez R, Carnevale A, Gonzalez-del Angel A et al. Cystic fibrosis: molecular update and clinical implications. Rev Invest Clin. 2006; 58 (2): 139-152.

  9. Dinwiddie R. Pathogenesis of lung disease in cystic fibrosis. Respiration. 2000; 67 (1): 3-8.

  10. Girón RM SA. Fibrosis Quística: atención integral, manejo clínico y puesta al día. Neumomadrid 2005. [Consulta 28 de septiembre de 2015] URL disponible en: http://www.neumomadrid.org/descargas/monog_neumomadrid_viii.pdf.

  11. Sánchez DI, Pérez H, Boza C, Lezana SV, Vila I, Repetto LG y cols. Consenso Nacional de Fibrosis Quística. Rev Chil Pediatr. 2001; 72: 356-380.

  12. Ratjen F, Döoring G. Cystic fibrosis. Lancet. 2003; 361 (9358): 681-689.

  13. Turner MW, Warner JO, Stokes CR. Immunological studies in cystic fibrosis. Arch Dis Child. 1978; 53 (8): 631-638.

  14. Matthews WJ, Williams M, Oliphint B, Geha R, Colten HR. Hypogammaglobulinemia in patients with cystic fibrosis. N Eng J Med. 1980; 302 (5): 245-249.

  15. Proesmans M, Els C, Vermeulen F, De Boeck K. Change in IgG and evolution of lung function in children with cystic fibrosis. J Cys Fibros. 2011; 10 (2): 128-131.

  16. Fick RB, Naegel GP, Squier SU, Wood RE, Gee BL, Reynolds HY. Proteins of the Cystic Fibrosis Respiratory Tract. Fragmented ImmunoglobulinG Opsonic Antibody Causing Defective Opsonophagocytosis. J Clin Invest. 1984; 74: 236-248.

  17. Cowan RG, Winnie GB. Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonar function, neutrophil chemotaxis, and phagocytosis. J Clin Immunol. 1993; 13 (5): 359-370.

  18. Aanaes K, Johansen HK, Poulsen SS, Pressler T, Buchwald C, Hoiby N. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros. 2013; 12 (1): 81-87.

  19. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 1999; 115 (4): 1053-1058.

  20. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2013; 6: Cd001505.

  21. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007; 176 (11): 1084-1089.

  22. Wong PH, White KM. Impact of Immunoglobulin Therapy in Pediatric Disease a Review of Immune Mechanisms. Clin Rev Allerg Immunol. doi 10.1007/s12016-015-8499-2. Published online 4 July 2015.

  23. Balfour-Lynn IM, Mohan U, Bush A, Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children. Arch Dise Child. 2004; 89 (4): 315-319.




2020     |     www.medigraphic.com